Baker McKenzie served as global counsel to Medtronic plc with the spin-off and carve-out of their diabetes division, MiniMed Group, Inc. MiniMed was valued at more than USD 5.3 billion at the end of its first day of trading on the Nasdaq on March 6, 2026.